When BC was compared with benign breast diseases, the combination of miR-34a (SN 36.2% and 34.0% at 90% and 95% SP, AUC = 0.719) with CEA or CA15-3 also resulted in improved performance (AUCs 0.794 and 0.741 respectively) (Zaleski et al. 2018). Here, CEACAM5 is linked to breast cancer.